WHO-GMP sourced EU-GMP partners ISO 9001:2015 49+ export markets Since 2003

Volibris and Letairis (ambrisentan) is an endothelin receptor antagonist for pulmonary arterial hypertension, supplied as 5 mg and 10 mg film-coated tablets taken once daily, with a pregnancy warning that shapes every order.

M Care Exports supplies Volibris and Letairis (ambrisentan) to hospital pharmacies, pulmonology and cardiology units, licensed importers and tender desks internationally, with established supply lanes into the GCC, Africa and Europe. If you are looking for Volibris 5 mg or ambrisentan 5 mg and 10 mg tablets, send the destination, the strength and the quantity, and we quote per destination, subject to the registration route and import licence your regulator requires.

WhatsApp an ambrisentan enquiry → Send enquiry by form
WHO-GMP sourcing CDSCO licensed exporter EU-GMP capable partners Cold-chain validated (2–8°C & −25°C) CTD / eCTD dossier-ready ISO 9001:2015
Bulk supply and export terms

Ambrisentan exporter and bulk supplier from India.

"We need a partner for Volibris" is a typical enquiry from a hospital pharmacy or a tender desk buying for pulmonary arterial hypertension (PAH). M Care is a merchant-exporter, and we supply both originator or regulator-registered brands and Indian-made lines of ambrisentan. Our catalogue lists Volibris 5 mg alongside Indian-made lines such as Pulmonext and Endobloc in 5 mg and 10 mg, and Ambrican in 5 mg. We do not claim those Indian-made brands are registered in any destination, so the first question on a quote is which product your regulator will accept. The UK SmPC states that the product does not require any special storage conditions, so it does not need a cold chain on that label. What moves the landed price is the choice between originator and another line, the strength, the pack, the quantity, the destination's registration route and Incoterms.

Source

WHO-GMP-certified Indian manufacturing line, named on every quote.

Minimum order

No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.

Pricing

On request. Indicative FOB or CIF quote, formal proforma on confirmation.

Incoterms

EXW, FOB, CIF, CIP or DAP.

Payment

Letter of credit (sight or usance) and telegraphic transfer.

Documentation

WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.

Shelf-life

Minimum remaining shelf-life agreed per order and confirmed on the proforma.

Response

Availability and CoPP status within two working days; pre-alert documents before dispatch.

Request a bulk quote → Send a bulk enquiry by form How bulk supply works
At a glance

Endothelin receptor antagonist, sourced and documented for export.

Ambrisentan is an endothelin receptor antagonist. The US label (Gilead Sciences, Letairis, DailyMed page updated June 2026) lists it for PAH (WHO Group 1) in adults: to improve exercise ability and delay clinical worsening, and in combination with tadalafil to reduce the risks of disease progression and hospitalisation for worsening PAH. Letairis comes as film-coated 5 mg (pale pink, square) and 10 mg (deep pink, oval) tablets, and the label says not to split, crush or chew them. The EU product Volibris (EMA page: GlaxoSmithKline Trading Services Limited, authorised 21 April 2008) is indicated for PAH in adults of WHO Functional Class II to III, including use in combination treatment, and for children and adolescents aged 8 to less than 18 years in the same functional classes. The UK emc SmPC for Volibris 5 mg lists GlaxoSmithKline UK Limited as holder, with a date of first authorisation or renewal of 1 January 2021, and unit dose blister packs of 10 or 30 tablets (not all pack sizes may be marketed).

Active ingredient

Ambrisentan. Endothelin receptor antagonist.

Forms and strengths

5 mg film-coated tablet; 10 mg film-coated tablet.

Indications

Ambrisentan is an endothelin receptor antagonist used for pulmonary arterial hypertension (WHO Group 1 in the US label; WHO Functional Class II to III in the EU and UK texts), alone or in combination treatment, including with tadalafil in the US label.

Administration

Oral. Film-coated tablet.

Documentation

Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.

Who we supply

Hospital pharmacies, licensed importers and tender desks across our export markets.

India is our origin. We do not sell into the Indian market.

Buyers are hospital pharmacists in pulmonology and cardiology, MoH and hospital tender desks, and licensed importers and distributors. Typical enquiries read "I'm looking for Volibris 5 mg for a PAH programme" or "We need a partner for ambrisentan 10 mg tablets for a tender". Each destination has its own route to registration or import, for example the Emirates Drug Establishment (EDE) in the UAE, NAFDAC in Nigeria and the MHRA in the UK, and we align the offer with it before quoting. The EMA states that Volibris is prescription-only and that treatment must be started by a doctor who has experience in the treatment of PAH. Whether a destination expects a registered product or accepts a named-patient or unlicensed import depends on the destination regulator, and M Care Exports confirms the route per enquiry.

GCC registration routes

Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.

MoH registration, GCC →

UK unlicensed routes

Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.

MHRA Specials →

Tender desks

Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.

Tender response →

Dossier support

CTD documentation from the sourcing manufacturer, compiled for your regulator's format.

Dossier preparation →

Pharmacist's note

What the dispensing pharmacist checks on ambrisentan.

Start with the label's dosing frame. The US label initiates at 5 mg once daily, with or without tadalafil 20 mg once daily, and says that at 4-week intervals either the ambrisentan dose or the tadalafil dose can be increased as needed and tolerated, to ambrisentan 10 mg or tadalafil 40 mg. With cyclosporine, the US label and the UK SmPC (cyclosporine A) limit ambrisentan to 5 mg once daily in adults. The pregnancy warning is the headline safety point. The US boxed warning is embryo-fetal toxicity: ambrisentan is contraindicated during pregnancy because it may cause major birth defects, pregnancy must be excluded before starting in females of reproductive potential, and effective contraception is advised before initiation, during treatment and for one month after stopping. The US label's recent-changes table shows the REMS section as removed in April 2025. The UK SmPC also contraindicates use in pregnancy and in women of child-bearing potential not using reliable contraception, and recommends monthly pregnancy tests. It further contraindicates breast-feeding, severe hepatic impairment, baseline ALT or AST above 3 times the upper limit of normal, idiopathic pulmonary fibrosis, and hypersensitivity to soya. The US label says to measure haemoglobin at initiation, at 1 month and periodically thereafter.

Regulatory & quality

The documentation pack a regulator actually asks for.

Ambrisentan is not a cold-chain product on the labels we read. The US label says to store at 25 C with excursions permitted to 15-30 C, in the original packaging. The UK SmPC says the medicinal product does not require any special storage conditions and gives a shelf life of 5 years. Export documentation follows the destination: batch certificates of analysis, packing lists and the dossier support a regulator asks for. Because presentation can differ between originator and Indian-made lines, we state the source and status of each line before quoting, and we make no claim that an Indian-made brand is registered anywhere. M Care Exports is a merchant-exporter, not the manufacturer, and we confirm manufacturer GMP status per line on request.

CoA and MoA, per batch

Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.

CoPP, WHO-GMP, MFG licence

Certificate of pharmaceutical product, site GMP certificate and manufacturing licence, issued by the state drug regulator and naming the actual manufacturing site.

CTD Module 3

Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.

Pack insert, labels, artwork

Destination-language patient information and labelling to the local regulator's standard, locked before shipment.

Pharmacovigilance

A named PV contact arranged in the destination market where the registration requires one.

How the enquiry works

Molecule · strength · volume · destination. One working day to a quote.

  1. Send us the specifics. Form and strength, pack preference, destination market and indicative volume for ambrisentan.
  2. We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
  3. Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
  4. Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
  5. After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Frequently asked

Ambrisentan supply, the specific questions.

Is there a generic of Volibris?

In the EU, the EMA lists Ambrisentan Viatris (previously Ambrisentan Mylan), authorised on 20 June 2019, as a generic medicine with Volibris as its reference medicine. In the US, Drugs@FDA gives Letairis a therapeutic equivalence code of AB, and FDA's Drugs@FDA data list approved generic ambrisentan tablets (ANDAs) from several companies, including Mylan, Cipla, Aurobindo, Zydus and Apotex. For the UK, we confirm which ambrisentan products the MHRA has authorised at the time of your enquiry. Whether a generic is accepted depends on the destination regulator. M Care Exports supplies Volibris as well as Indian-made ambrisentan lines, and confirms per enquiry which your destination will take.

What is the price of Volibris for an importer?

We do not publish prices. The landed price depends on whether you want the originator Volibris or another line, the strength (5 mg or 10 mg), the pack size, the quantity, the registration route in your destination and Incoterms. The UK SmPC states no special storage conditions, which keeps freight simpler. M Care Exports quotes per destination once we have the strength, pack and quantity.

Is Volibris the same as Letairis?

Both contain ambrisentan. Volibris is the name used in the EU and UK (the EMA page lists GlaxoSmithKline Trading Services Limited as holder) and Letairis is the US brand from Gilead Sciences. The labels differ in detail. The US label covers adults with PAH (WHO Group 1), while the EU text uses WHO Functional Class II to III and adds children and adolescents aged 8 to less than 18 years. We quote whichever your destination registers or accepts.

Which strengths and presentations are available?

The US label lists 5 mg and 10 mg film-coated tablets, with blister and bottle packs of 10 and 30. The UK emc page for Volibris lists unit dose blister packs of 10 or 30 tablets and notes that not all pack sizes may be marketed. Our catalogue has Volibris 5 mg and Indian-made 5 mg and 10 mg lines. Send the strength and pack you need and we confirm what can be supplied.

Does ambrisentan need cold-chain shipping?

The UK SmPC states that the medicinal product does not require any special storage conditions, and the US label says to store at 25 C with excursions permitted to 15-30 C, in the original packaging. That makes ambrisentan a lower logistics burden than refrigerated products, though destination import rules still apply.

What does the label say about pregnancy and importing for PAH programmes?

The US boxed warning says ambrisentan is contraindicated during pregnancy because it may cause major birth defects, that pregnancy must be excluded before treatment in females of reproductive potential, and that effective contraception is advised before initiation, during treatment and for one month after stopping. The UK SmPC also contraindicates use in pregnancy and in women of child-bearing potential without reliable contraception. Pharmacy teams should plan counselling and patient information with the label for their destination. M Care Exports confirms the registration or import route per enquiry.

Sources and review

Who stands behind this page, and where its statements come from.

Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-11-15.

This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.

Ambrisentan enquiry

Send the specifics. You'll have a price inside one working day.

Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.

WhatsApp the Mumbai desk → Enquiry form Back to cardiovascular